Vertex Pharmaceuticals Incorporated (FRA:VX1)
Germany · Delayed Price · Currency is EUR | Market Cap | 94.12B |
| Revenue (ttm) | 9.72B |
| Net Income (ttm) | 3.10B |
| Shares Out | n/a |
| EPS (ttm) | 11.98 |
| PE Ratio | 30.39 |
| Forward PE | 21.84 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 137 |
| Average Volume | 131 |
| Open | 347.40 |
| Previous Close | 351.55 |
| Day's Range | 347.10 - 350.85 |
| 52-Week Range | 313.75 - 487.00 |
| Beta | n/a |
| RSI | 61.72 |
| Earnings Date | Nov 3, 2025 |
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The com... [Read more]
News
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $407.9, denoting a -1.05% move from the preceding trading day.
Vertex Pharmaceuticals (VRTX): Analyst Rating Update from Morgan Stanley | VRTX Stock News
Vertex Pharmaceuticals (VRTX): Analyst Rating Update from Morgan Stanley | VRTX Stock News
VRTX: JP Morgan Raises Price Target to $530 | VRTX Stock News
VRTX: JP Morgan Raises Price Target to $530 | VRTX Stock News
Spotlight on Vertex Pharmaceuticals: Analyzing the Surge in Options Activity
Whales with a lot of money to spend have taken a noticeably bullish stance on Vertex Pharmaceuticals . Looking at options history for Vertex Pharmaceuticals (NASDAQ: VRTX) we detected 10 trades. If w...
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Vertex to Announce Third Quarter 2025 Financial Results on November 3rd
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2025 financial results on Monday, November 3, 2025, after the financial markets close. The com...
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years
Vertex Pharmaceuticals (NASDAQ: VRTX) has outperformed the market over the past 20 years by 6.5% on an annualized basis producing an average annual return of 15.61%. Currently, Vertex Pharmaceuticals...
Noteworthy ETF Outflows: VUG, SYK, BX, VRTX
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Growth ETF (Symbol: VUG) where we have detected an approximat...
Insider Sell: Jonathan Biller Sells Shares of Vertex Pharmaceuticals Inc (VRTX)
Insider Sell: Jonathan Biller Sells Shares of Vertex Pharmaceuticals Inc (VRTX)
Vertex Pharmaceuticals (VRTX) Stock Dips While Market Gains: Key Facts
In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $403.3, indicating a -1.36% shift from the previous trading day.
ServiceNow, Vertex Pharmaceuticals And More: CNBC's 'Final Trades'
On CNBC's “ Halftime Report Final Trades ,” on Thursday, Jason Snipe , founder and chief investment officer of Odyssey Capital Advisors, said he likes ServiceNow, Inc. (NYSE: NOW), which is down 14% ...
Vertex Pharmaceuticals (VRTX) Exceeds Market Returns: Some Facts to Consider
The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $408.85, representing a +1.15% change from its previous close.
Vertex Pharmaceuticals (VRTX) Receives Raised Price Target from Citigroup | VRTX Stock News
Vertex Pharmaceuticals (VRTX) Receives Raised Price Target from Citigroup | VRTX Stock News
Final Trades: ServiceNow, Vertex Pharmaceuticals and the IJR
CNBC's “Halftime Report” team discuss their top stocks and final trades.
Final Trades: ServiceNow, Vertex Pharmaceuticals and the IJR
CNBCs Halftime Report team discuss their top stocks and final trades.
Vertex (VRTX) Is Considered a Good Investment by Brokers: Is That True?
Based on the average brokerage recommendation (ABR), Vertex (VRTX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this h...
Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet
Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-dependent compa...
Vertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to Note
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $381.87, denoting a +1.39% move from the preceding trading day.
Vertex Pharmaceuticals: Trikafta And Alyftrek Cement Market Leadership
Vertex's revenue was $2.96 billion in the second quarter of 2025, beating the consensus forecast by $58 million. Click here to find out why VRTX is a Buy.
Vertex (VRTX) Initiates Phase 2 Study for ADPKD Treatment
Vertex (VRTX) Initiates Phase 2 Study for ADPKD Treatment
Vertex (VRTX) Completes Enrollment in Key Phase 2/3 Kidney Trial
Vertex (VRTX) Completes Enrollment in Key Phase 2/3 Kidney Trial
Vertex Pharmaceuticals (VRTX) Gains FDA Breakthrough Therapy Designation
Vertex Pharmaceuticals (VRTX) Gains FDA Breakthrough Therapy Designation
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Vertex Pharmaceuticals (VRTX) Receives Analyst Upgrade and PT Adjustment | VRTX Stock News
Vertex Pharmaceuticals (VRTX) Receives Analyst Upgrade and PT Adjustment | VRTX Stock News
Vertex Announces Key Advancements Across Kidney Portfolio
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important advancements across its programs in immunoglobulin A Nephropathy (IgAN), APOL1-mediated ki...